DBV Technologies SA (NAS:DBVT)
$ 0.5763 -0.0132 (-2.24%) Market Cap: 128.96 Mil Enterprise Value: 31.73 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 38/100

DBV Technologies SA To Provide Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children Corporate Call Transcript

Feb 13, 2019 / 09:30PM GMT
Release Date Price: $7.05 (-0.84%)
Operator

Welcome to the DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age. My name is James. I'll be your operator for today's call. (Operator Instructions)

Also note that this conference is being recorded. And now I'd like to turn the call over to Susanna Mesa. Susanna, you may begin.

Susanna Mesa
DBV Technologies S.A. - Chief Business Officer

Thank you, James, and thank you all of you for joining today's call. Earlier today, we issued a press release providing our new update on the anticipated regulatory pathway for Viaskin Peanut, our lead product candidate for the treatment of peanut-allergic children 4 to 11 years of age. This press release is available in our website at dbv-technologies.com as well as the SEC website. Joining me on the call today are our CEO, Daniel Tassé; and our Manufacturing and Operations Leader, Julie OâNeill. Daniel and Julie will each deliver remarks, and then we'll open the call for Q&A.

Before we start, I would like to note

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot